You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSunitinib
Accession NumberDB01268  (DB07417)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionSunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Structure
Thumb
Synonyms
Sunitinibum
External Identifiers
  • SU-011248
  • SU-11248
  • SU011248
  • SU11248
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sutentcapsule37.5 mgoralPfizer Canada IncNot applicableNot applicableCanada
SutentCapsule, hard37.5 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule12.5 mg/1oralPfizer Laboratories Div Pfizer Inc2006-01-26Not applicableUs
SutentCapsule, hard12.5 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule12.5 mgoralPfizer Canada Inc2006-06-22Not applicableCanada
SutentCapsule, hard12.5 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule25 mg/1oralPfizer Laboratories Div Pfizer Inc2006-01-26Not applicableUs
SutentCapsule, hard25 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule25 mgoralPfizer Canada Inc2006-06-22Not applicableCanada
SutentCapsule, hard25 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule37.5 mg/1oralPfizer Laboratories Div Pfizer Inc2014-07-12Not applicableUs
SutentCapsule, hard50 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule50 mgoralPfizer Canada Inc2006-06-22Not applicableCanada
SutentCapsule, hard50 mgOral usePfizer Limited2006-07-19Not applicableEu
Sutentcapsule50 mg/1oralPfizer Laboratories Div Pfizer Inc2006-01-26Not applicableUs
SutentCapsule, hard37.5 mgOral usePfizer Limited2006-07-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sunitinib malate
341031-54-7
Thumb
  • InChI Key: LBWFXVZLPYTWQI-IPOVEDGCSA-N
  • Monoisotopic Mass: 532.233327635
  • Average Mass: 532.5612
DBSALT000166
Categories
UNIIV99T50803M
CAS number557795-19-4
WeightAverage: 398.4738
Monoisotopic: 398.211804333
Chemical FormulaC22H27FN4O2
InChI KeyInChIKey=WINHZLLDWRZWRT-ATVHPVEESA-N
InChI
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
IUPAC Name
N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide
SMILES
CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indolines. These are compounds containing an indole moiety, which consists of pyrrolidine ring fused to benzene to form 2,3-dihydroindole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndolines
Direct ParentIndolines
Alternative Parents
Substituents
  • Dihydroindole
  • Pyrrole-3-carboxylic acid or derivatives
  • Pyrrole-3-carboxamide
  • Fluorobenzene
  • Benzenoid
  • Substituted pyrrole
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
PharmacodynamicsSunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA on January 26, 2006.
Mechanism of actionSunitinib is a small molecule that inhibits multiple RTKs, some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.
Related Articles
AbsorptionMaximum plasma concentrations (Cmax) of sunitinib are generally observed between 6 and 12 hours (Tmax) following oral administration. Food has no effect on the bioavailability of sunitinib. Sunitinib may be taken with or without food. The pharmacokinetics were similar in healthy volunteers and in the solid tumor patient populations tested, including patients with GIST and RCC.
Volume of distribution
  • 2230 L (apparent volume of distribution, Vd/F)
Protein bindingBinding of sunitinib and its primary metabolite to human plasma protein in vitro was 95% and 90%, respectively.
Metabolism

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4.

Route of eliminationSunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4. Elimination is primarily via feces. In a human mass balance study of [14C]sunitinib, 61% of the dose was eliminated in feces, with renal elimination accounting for 16% of the administered dose.
Half lifeFollowing administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.
Clearance
  • 34 – 62 L/h [Total oral clearance]
ToxicityThe maximally tolerated dose for rat, mouse, and dog when given orally is greater than 500 mg/kg. The maximally tolerated dose of a non-human primate is greater 1200 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9938
Blood Brain Barrier+0.7993
Caco-2 permeable-0.5948
P-glycoprotein substrateSubstrate0.8648
P-glycoprotein inhibitor IInhibitor0.6809
P-glycoprotein inhibitor IINon-inhibitor0.5466
Renal organic cation transporterNon-inhibitor0.7385
CYP450 2C9 substrateNon-substrate0.8727
CYP450 2D6 substrateNon-substrate0.7716
CYP450 3A4 substrateSubstrate0.641
CYP450 1A2 substrateNon-inhibitor0.5626
CYP450 2C9 inhibitorNon-inhibitor0.6437
CYP450 2D6 inhibitorNon-inhibitor0.6846
CYP450 2C19 inhibitorNon-inhibitor0.6261
CYP450 3A4 inhibitorNon-inhibitor0.5991
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7032
Ames testNon AMES toxic0.5699
CarcinogenicityNon-carcinogens0.784
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6794 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8597
hERG inhibition (predictor II)Inhibitor0.8398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral12.5 mg/1
Capsuleoral12.5 mg
Capsuleoral25 mg
Capsuleoral25 mg/1
Capsuleoral37.5 mg
Capsuleoral37.5 mg/1
Capsuleoral50 mg/1
Capsuleoral50 mg
Capsule, hardOral use12.5 mg
Capsule, hardOral use25 mg
Capsule, hardOral use37.5 mg
Capsule, hardOral use50 mg
Prices
Unit descriptionCostUnit
Sutent 50 mg capsule333.39USD capsule
Sutent 25 mg capsule187.28USD capsule
Sutent 12.5 mg capsule93.64USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2395461 No2010-05-252020-12-22Canada
CA2399358 No2006-03-212021-02-15Canada
US6573293 No2001-02-152021-02-15Us
US7125905 No2001-02-152021-02-15Us
US7211600 No2000-12-222020-12-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility>25 mg/mL over pH of 1.2 to 6.8FDA label
logP5.2 FDA label
pKa8.95 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0308 mg/mLALOGPS
logP3.24ALOGPS
logP2.93ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)11.46ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.23 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity116.27 m3·mol-1ChemAxon
Polarizability44.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ettore BIGATTI, Augusto CANAVESI, Peter Lindsay MACDONALD, Francesca Scarpitta, “PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF.” U.S. Patent US20090247767, issued October 01, 2009.

US20090247767
General References
  1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. [PubMed:17215529 ]
  2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. [PubMed:17046465 ]
External Links
ATC CodesL01XE04
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (159 KB)
MSDSDownload (98.3 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Sunitinib can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Sunitinib can be decreased when combined with 2-mercaptobenzothiazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Sunitinib.
AcarboseAcarbose may increase the hypoglycemic activities of Sunitinib.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Sunitinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Sunitinib.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Sunitinib.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sunitinib.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Sunitinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Sunitinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sunitinib.
AicarAicar may increase the hypoglycemic activities of Sunitinib.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Sunitinib.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Sunitinib.
AlogliptinAlogliptin may increase the hypoglycemic activities of Sunitinib.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Sunitinib.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Sunitinib.
AmiodaroneThe metabolism of Sunitinib can be decreased when combined with Amiodarone.
AmiodaroneSunitinib may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Sunitinib.
AmorolfineThe metabolism of Sunitinib can be decreased when combined with Amorolfine.
AmoxapineAmoxapine may increase the hypoglycemic activities of Sunitinib.
Amphotericin BThe metabolism of Sunitinib can be decreased when combined with Amphotericin B.
AN2690The metabolism of Sunitinib can be decreased when combined with AN2690.
AnagrelideSunitinib may increase the QTc-prolonging activities of Anagrelide.
AnidulafunginThe metabolism of Sunitinib can be decreased when combined with Anidulafungin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sunitinib.
AprepitantThe serum concentration of Sunitinib can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Sunitinib.
ArtemetherThe metabolism of Sunitinib can be decreased when combined with Artemether.
ArtemetherSunitinib may increase the QTc-prolonging activities of Artemether.
AsenapineSunitinib may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Sunitinib can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Sunitinib.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Sunitinib.
AtomoxetineThe metabolism of Sunitinib can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Sunitinib.
AzithromycinSunitinib may increase the QTc-prolonging activities of Azithromycin.
Bafilomycin A1The metabolism of Sunitinib can be decreased when combined with Bafilomycin A1.
BedaquilineSunitinib may increase the QTc-prolonging activities of Bedaquiline.
BenmoxinBenmoxin may increase the hypoglycemic activities of Sunitinib.
Benzoic AcidThe metabolism of Sunitinib can be decreased when combined with Benzoic Acid.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Sunitinib.
BevacizumabThe risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.
BevacizumabBevacizumab may increase the cardiotoxic activities of Sunitinib.
BexaroteneThe serum concentration of Sunitinib can be decreased when it is combined with Bexarotene.
BifonazoleThe metabolism of Sunitinib can be decreased when combined with Bifonazole.
BoceprevirThe metabolism of Sunitinib can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Sunitinib.
BortezomibThe metabolism of Sunitinib can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sunitinib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sunitinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sunitinib.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Sunitinib.
BuforminBuformin may increase the hypoglycemic activities of Sunitinib.
ButenafineThe metabolism of Sunitinib can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Sunitinib can be decreased when combined with Butoconazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Sunitinib.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sunitinib.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Sunitinib.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sunitinib.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Sunitinib.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Sunitinib.
CandicidinThe metabolism of Sunitinib can be decreased when combined with Candicidin.
CarbamazepineThe serum concentration of Sunitinib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Sunitinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Sunitinib.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Sunitinib.
CaspofunginThe metabolism of Sunitinib can be decreased when combined with Caspofungin.
CastanospermineCastanospermine may increase the hypoglycemic activities of Sunitinib.
CeritinibThe serum concentration of Sunitinib can be increased when it is combined with Ceritinib.
CeritinibSunitinib may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sunitinib.
CeruleninThe metabolism of Sunitinib can be decreased when combined with Cerulenin.
ChloroquineSunitinib may increase the QTc-prolonging activities of Chloroquine.
ChloroxineThe metabolism of Sunitinib can be decreased when combined with Chloroxine.
ChlorpromazineSunitinib may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Sunitinib.
CiclopiroxThe metabolism of Sunitinib can be decreased when combined with Ciclopirox.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Sunitinib.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Sunitinib.
CiprofloxacinSunitinib may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideSunitinib may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Sunitinib.
CitalopramCitalopram may increase the hypoglycemic activities of Sunitinib.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Sunitinib.
ClarithromycinSunitinib may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Sunitinib can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Sunitinib can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Sunitinib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Sunitinib.
ClomipramineClomipramine may increase the hypoglycemic activities of Sunitinib.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Sunitinib.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Sunitinib.
ClotrimazoleThe metabolism of Sunitinib can be decreased when combined with Clotrimazole.
ClozapineSunitinib may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Sunitinib can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sunitinib.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sunitinib.
ConivaptanThe serum concentration of Sunitinib can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sunitinib.
CrizotinibSunitinib may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Sunitinib can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sunitinib.
CyclosporineThe metabolism of Sunitinib can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Sunitinib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sunitinib.
DabrafenibThe serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Sunitinib.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Sunitinib.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Sunitinib.
DapoxetineDapoxetine may increase the hypoglycemic activities of Sunitinib.
DarunavirThe metabolism of Sunitinib can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Sunitinib can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Sunitinib.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Sunitinib.
Decanoic AcidThe metabolism of Sunitinib can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Sunitinib can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Sunitinib can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Sunitinib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sunitinib.
DexamethasoneThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Sunitinib.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Sunitinib.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sunitinib.
DiflunisalDiflunisal may increase the hypoglycemic activities of Sunitinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sunitinib.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Sunitinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Sunitinib.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sunitinib.
DihydroergotamineThe metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Sunitinib.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Sunitinib.
DiltiazemThe metabolism of Sunitinib can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Sunitinib.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Sunitinib.
DisopyramideDisopyramide may increase the hypoglycemic activities of Sunitinib.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sunitinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.
DofetilideSunitinib may increase the QTc-prolonging activities of Dofetilide.
DolasetronSunitinib may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sunitinib.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sunitinib.
DoxycyclineThe metabolism of Sunitinib can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Sunitinib can be decreased when combined with Dronedarone.
DronedaroneSunitinib may increase the QTc-prolonging activities of Dronedarone.
DroperidolSunitinib may increase the QTc-prolonging activities of Droperidol.
DulaglutideDulaglutide may increase the hypoglycemic activities of Sunitinib.
EconazoleThe metabolism of Sunitinib can be decreased when combined with Econazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sunitinib.
EfavirenzThe serum concentration of Sunitinib can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Sunitinib can be decreased when combined with Efinaconazole.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sunitinib.
EliglustatSunitinib may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Sunitinib.
EnzalutamideThe serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Sunitinib.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Sunitinib.
ErythromycinSunitinib may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Sunitinib can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Sunitinib.
EscitalopramSunitinib may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Sunitinib can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Sunitinib.
EstriolThe serum concentration of Estriol can be increased when it is combined with Sunitinib.
EstroneThe serum concentration of Estrone can be increased when it is combined with Sunitinib.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sunitinib.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Sunitinib.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Sunitinib.
EtravirineThe serum concentration of Sunitinib can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sunitinib.
ExenatideExenatide may increase the hypoglycemic activities of Sunitinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Sunitinib.
FenfluramineFenfluramine may increase the hypoglycemic activities of Sunitinib.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Sunitinib.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Sunitinib.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Sunitinib.
FingolimodSunitinib may increase the immunosuppressive activities of Fingolimod.
FlecainideSunitinib may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe metabolism of Sunitinib can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Sunitinib can be decreased when combined with Flucytosine.
FluoxetineFluoxetine may increase the hypoglycemic activities of Sunitinib.
FluoxetineSunitinib may increase the QTc-prolonging activities of Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Sunitinib.
FlupentixolSunitinib may increase the QTc-prolonging activities of Flupentixol.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Sunitinib.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Sunitinib.
FosamprenavirThe metabolism of Sunitinib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sunitinib can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Sunitinib can be decreased when it is combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Sunitinib.
Fusidic AcidThe serum concentration of Sunitinib can be increased when it is combined with Fusidic Acid.
Gadobenic acidSunitinib may increase the QTc-prolonging activities of Gadobenic acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sunitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Sunitinib.
GemifloxacinSunitinib may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideGlibornuride may increase the hypoglycemic activities of Sunitinib.
GliclazideGliclazide may increase the hypoglycemic activities of Sunitinib.
GlimepirideGlimepiride may increase the hypoglycemic activities of Sunitinib.
GlipizideGlipizide may increase the hypoglycemic activities of Sunitinib.
GliquidoneGliquidone may increase the hypoglycemic activities of Sunitinib.
GlyburideGlyburide may increase the hypoglycemic activities of Sunitinib.
GlyphosateThe metabolism of Sunitinib can be decreased when combined with Glyphosate.
GoserelinSunitinib may increase the QTc-prolonging activities of Goserelin.
GranisetronSunitinib may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Sunitinib.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Sunitinib.
GriseofulvinThe metabolism of Sunitinib can be decreased when combined with Griseofulvin.
HaloperidolSunitinib may increase the QTc-prolonging activities of Haloperidol.
HaloproginThe metabolism of Sunitinib can be decreased when combined with Haloprogin.
HexetidineThe metabolism of Sunitinib can be decreased when combined with Hexetidine.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Sunitinib.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Sunitinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Sunitinib.
IbutilideSunitinib may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Sunitinib can be increased when it is combined with Idelalisib.
IloperidoneSunitinib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Sunitinib can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sunitinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Sunitinib.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Sunitinib.
IndalpineIndalpine may increase the hypoglycemic activities of Sunitinib.
IndinavirThe metabolism of Sunitinib can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Sunitinib.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Sunitinib.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Sunitinib.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Sunitinib.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Sunitinib.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Sunitinib.
Insulin HumanInsulin Human may increase the hypoglycemic activities of Sunitinib.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Sunitinib.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Sunitinib.
IproclozideIproclozide may increase the hypoglycemic activities of Sunitinib.
IproniazidIproniazid may increase the hypoglycemic activities of Sunitinib.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Sunitinib.
IsavuconazoniumThe metabolism of Sunitinib can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Sunitinib.
IsoconazoleThe metabolism of Sunitinib can be decreased when combined with Isoconazole.
IsradipineThe metabolism of Sunitinib can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Sunitinib can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Sunitinib can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Sunitinib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Sunitinib.
KetoconazoleThe metabolism of Sunitinib can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Sunitinib.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sunitinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Sunitinib.
LanreotideSunitinib may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Sunitinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sunitinib.
LeflunomideThe risk or severity of adverse effects can be increased when Sunitinib is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Sunitinib.
LenvatinibSunitinib may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideSunitinib may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Sunitinib.
LevofloxacinSunitinib may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Sunitinib.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Sunitinib.
LinagliptinLinagliptin may increase the hypoglycemic activities of Sunitinib.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Sunitinib.
LiraglutideLiraglutide may increase the hypoglycemic activities of Sunitinib.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Sunitinib.
LopinavirThe metabolism of Sunitinib can be decreased when combined with Lopinavir.
LopinavirSunitinib may increase the QTc-prolonging activities of Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Sunitinib.
LovastatinThe metabolism of Sunitinib can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Sunitinib.
LuliconazoleThe serum concentration of Sunitinib can be increased when it is combined with Luliconazole.
LumefantrineSunitinib may increase the QTc-prolonging activities of Lumefantrine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Sunitinib.
MebanazineMebanazine may increase the hypoglycemic activities of Sunitinib.
MecaserminSunitinib may increase the hypoglycemic activities of Mecasermin.
MesalazineMesalazine may increase the hypoglycemic activities of Sunitinib.
MetforminMetformin may increase the hypoglycemic activities of Sunitinib.
MethadoneSunitinib may increase the QTc-prolonging activities of Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sunitinib.
Methylene blueMethylene blue may increase the hypoglycemic activities of Sunitinib.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Sunitinib.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sunitinib.
MevastatinThe metabolism of Sunitinib can be decreased when combined with Mevastatin.
MicafunginThe metabolism of Sunitinib can be decreased when combined with Micafungin.
MiconazoleThe metabolism of Sunitinib can be decreased when combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Sunitinib.
MifepristoneMifepristone may increase the hypoglycemic activities of Sunitinib.
MiglitolMiglitol may increase the hypoglycemic activities of Sunitinib.
MiglustatMiglustat may increase the hypoglycemic activities of Sunitinib.
MilnacipranMilnacipran may increase the hypoglycemic activities of Sunitinib.
MiltefosineThe metabolism of Sunitinib can be decreased when combined with Miltefosine.
MinaprineMinaprine may increase the hypoglycemic activities of Sunitinib.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Sunitinib.
MitiglinideMitiglinide may increase the hypoglycemic activities of Sunitinib.
MitotaneThe serum concentration of Sunitinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Sunitinib.
MoclobemideMoclobemide may increase the hypoglycemic activities of Sunitinib.
ModafinilThe serum concentration of Sunitinib can be decreased when it is combined with Modafinil.
MonensinThe metabolism of Sunitinib can be decreased when combined with Monensin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Sunitinib.
MoxifloxacinSunitinib may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sunitinib.
MyxothiazolThe metabolism of Sunitinib can be decreased when combined with Myxothiazol.
NadololThe serum concentration of Nadolol can be increased when it is combined with Sunitinib.
NafcillinThe serum concentration of Sunitinib can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Sunitinib can be decreased when combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sunitinib.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Sunitinib.
NatalizumabThe risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.
NatamycinThe metabolism of Sunitinib can be decreased when combined with Natamycin.
NateglinideNateglinide may increase the hypoglycemic activities of Sunitinib.
NefazodoneThe metabolism of Sunitinib can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Sunitinib can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Sunitinib.
NetupitantThe serum concentration of Sunitinib can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Sunitinib can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypoglycemic activities of Sunitinib.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Sunitinib.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Sunitinib.
NilotinibThe metabolism of Sunitinib can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Sunitinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sunitinib.
NitroxolineThe metabolism of Sunitinib can be decreased when combined with Nitroxoline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Sunitinib.
NystatinThe metabolism of Sunitinib can be decreased when combined with Nystatin.
OctamoxinOctamoxin may increase the hypoglycemic activities of Sunitinib.
OctreotideOctreotide may increase the hypoglycemic activities of Sunitinib.
OfloxacinSunitinib may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Sunitinib.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Sunitinib.
OlaparibThe metabolism of Sunitinib can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sunitinib.
OndansetronSunitinib may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Sunitinib can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Sunitinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Sunitinib.
OxiconazoleThe metabolism of Sunitinib can be decreased when combined with Oxiconazole.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Sunitinib.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Sunitinib.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sunitinib.
pafuramidineThe metabolism of Sunitinib can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Sunitinib can be increased when it is combined with Palbociclib.
PaliperidoneSunitinib may increase the QTc-prolonging activities of Paliperidone.
PanobinostatSunitinib may increase the QTc-prolonging activities of Panobinostat.
PargylinePargyline may increase the hypoglycemic activities of Sunitinib.
ParoxetineParoxetine may increase the hypoglycemic activities of Sunitinib.
PasireotideSunitinib may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sunitinib.
PegvisomantPegvisomant may increase the hypoglycemic activities of Sunitinib.
PentamidineSunitinib may increase the QTc-prolonging activities of Pentamidine.
PentamidinePentamidine may increase the hypoglycemic activities of Sunitinib.
PentobarbitalThe serum concentration of Sunitinib can be decreased when it is combined with Pentobarbital.
PerflutrenSunitinib may increase the QTc-prolonging activities of Perflutren.
PhenelzinePhenelzine may increase the hypoglycemic activities of Sunitinib.
PhenforminPhenformin may increase the hypoglycemic activities of Sunitinib.
PheniprazinePheniprazine may increase the hypoglycemic activities of Sunitinib.
PhenobarbitalThe serum concentration of Sunitinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Sunitinib.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Sunitinib.
PhenytoinThe serum concentration of Sunitinib can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Sunitinib.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sunitinib.
PimozideSunitinib may increase the QTc-prolonging activities of Pimozide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Sunitinib.
PirlindolePirlindole may increase the hypoglycemic activities of Sunitinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sunitinib.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Sunitinib.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Sunitinib.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Sunitinib.
PosaconazoleThe metabolism of Sunitinib can be decreased when combined with Posaconazole.
PramlintidePramlintide may increase the hypoglycemic activities of Sunitinib.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Sunitinib.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Sunitinib.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Sunitinib.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Sunitinib.
PrimaquineSunitinib may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Sunitinib can be decreased when it is combined with Primidone.
ProcainamideSunitinib may increase the QTc-prolonging activities of Procainamide.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Sunitinib.
PromazineSunitinib may increase the QTc-prolonging activities of Promazine.
PropafenoneSunitinib may increase the QTc-prolonging activities of Propafenone.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Sunitinib.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sunitinib.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Sunitinib.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Sunitinib.
QuinineQuinine may increase the hypoglycemic activities of Sunitinib.
Rabies vaccineThe risk or severity of adverse effects can be increased when Sunitinib is combined with Rabies vaccine.
RadicicolThe metabolism of Sunitinib can be decreased when combined with Radicicol.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Sunitinib.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sunitinib.
RanolazineThe metabolism of Sunitinib can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypoglycemic activities of Sunitinib.
RepaglinideRepaglinide may increase the hypoglycemic activities of Sunitinib.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Sunitinib.
RifabutinThe serum concentration of Sunitinib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Sunitinib can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Sunitinib.
RifapentineThe serum concentration of Sunitinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sunitinib.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Sunitinib.
RitonavirThe metabolism of Sunitinib can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Sunitinib.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Sunitinib.
RoflumilastRoflumilast may increase the immunosuppressive activities of Sunitinib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Sunitinib.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Sunitinib.
SafrazineSafrazine may increase the hypoglycemic activities of Sunitinib.
Salicylhydroxamic AcidThe metabolism of Sunitinib can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Sunitinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Sunitinib.
SaquinavirSunitinib may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Sunitinib can be decreased when combined with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Sunitinib.
SelegilineSelegiline may increase the hypoglycemic activities of Sunitinib.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Sunitinib.
SertaconazoleThe metabolism of Sunitinib can be decreased when combined with Sertaconazole.
SertralineSertraline may increase the hypoglycemic activities of Sunitinib.
SildenafilThe metabolism of Sunitinib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sunitinib.
SiltuximabThe serum concentration of Sunitinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sunitinib can be increased when it is combined with Simeprevir.
SinefunginThe metabolism of Sunitinib can be decreased when combined with Sinefungin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sunitinib.
SirolimusThe metabolism of Sunitinib can be decreased when combined with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Sunitinib.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Sunitinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sunitinib.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Sunitinib.
SotalolSunitinib may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Sunitinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Sunitinib.
St. John's WortThe serum concentration of Sunitinib can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Sunitinib.
StiripentolThe serum concentration of Sunitinib can be increased when it is combined with Stiripentol.
SulconazoleThe metabolism of Sunitinib can be decreased when combined with Sulconazole.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Sunitinib.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Sunitinib.
SulfisoxazoleSunitinib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Sunitinib.
SulodexideSulodexide may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Sunitinib.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Sunitinib.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Sunitinib.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Sunitinib.
TavaboroleThe metabolism of Sunitinib can be decreased when combined with Tavaborole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sunitinib.
TelaprevirThe metabolism of Sunitinib can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Sunitinib.
TelavancinSunitinib may increase the QTc-prolonging activities of Telavancin.
TelithromycinSunitinib may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Sunitinib can be decreased when combined with Telithromycin.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Sunitinib.
TerbinafineThe metabolism of Sunitinib can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Sunitinib can be decreased when combined with Terconazole.
TestosteroneTestosterone may increase the hypoglycemic activities of Sunitinib.
TetrabenazineSunitinib may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineSunitinib may increase the QTc-prolonging activities of Thioridazine.
ThymolThe metabolism of Sunitinib can be decreased when combined with Thymol.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Sunitinib.
TiclopidineThe metabolism of Sunitinib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Sunitinib.
TioconazoleThe metabolism of Sunitinib can be decreased when combined with Tioconazole.
TocilizumabThe serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.
TofacitinibSunitinib may increase the immunosuppressive activities of Tofacitinib.
TolazamideTolazamide may increase the hypoglycemic activities of Sunitinib.
TolbutamideTolbutamide may increase the hypoglycemic activities of Sunitinib.
TolnaftateThe metabolism of Sunitinib can be decreased when combined with Tolnaftate.
ToloxatoneToloxatone may increase the hypoglycemic activities of Sunitinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sunitinib.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sunitinib.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Sunitinib.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sunitinib.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Sunitinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Sunitinib.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Sunitinib.
TrazodoneTrazodone may increase the hypoglycemic activities of Sunitinib.
TrimetrexateThe metabolism of Sunitinib can be decreased when combined with Trimetrexate.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Sunitinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sunitinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Sunitinib.
VandetanibSunitinib may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Sunitinib.
VemurafenibSunitinib may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Sunitinib can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Sunitinib.
VerapamilThe metabolism of Sunitinib can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Sunitinib.
VilazodoneVilazodone may increase the hypoglycemic activities of Sunitinib.
VildagliptinVildagliptin may increase the hypoglycemic activities of Sunitinib.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Sunitinib.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sunitinib.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Sunitinib.
VogliboseVoglibose may increase the hypoglycemic activities of Sunitinib.
VoriconazoleThe metabolism of Sunitinib can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the hypoglycemic activities of Sunitinib.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Sunitinib.
ZimelidineZimelidine may increase the hypoglycemic activities of Sunitinib.
ZiprasidoneThe metabolism of Sunitinib can be decreased when combined with Ziprasidone.
ZiprasidoneSunitinib may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolSunitinib may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. [PubMed:12538485 ]
  2. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003 May;2(5):471-8. [PubMed:12748309 ]
  3. Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
  4. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005 Feb 10;23(5):939-52. Epub 2004 Nov 22. [PubMed:15557593 ]
  5. Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. [PubMed:16425993 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vegf-b-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:
FLT1
Uniprot ID:
P17948
Molecular Weight:
150767.185 Da
References
  1. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76. [PubMed:14654525 ]
  2. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003 May;2(5):471-8. [PubMed:12748309 ]
  2. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16. [PubMed:12873999 ]
  3. Joensuu H: Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol. 2007 Jul;19(4):353-8. [PubMed:17545799 ]
  4. Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
  5. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. [PubMed:12538485 ]
  2. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16. [PubMed:12873999 ]
  3. Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
  4. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. [PubMed:16418310 ]
  5. Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M: YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 2006 Mar 1;12(5):1630-8. [PubMed:16533791 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:
FLT4
Uniprot ID:
P35916
Molecular Weight:
152755.94 Da
References
  1. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
  2. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007 Jul 2;5:32. [PubMed:17605814 ]
  3. Katoh Y, Katoh M: Comparative integromics on VEGF family members. Int J Oncol. 2006 Jun;28(6):1585-9. [PubMed:16685460 ]
  4. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200. [PubMed:17296815 ]
  5. Ahmed SI, Thomas AL, Steward WP: Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother. 2004 Nov;16 Suppl 4:59-63. [PubMed:15688612 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or...
Gene Name:
FLT3
Uniprot ID:
P36888
Molecular Weight:
112902.51 Da
References
  1. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16. [PubMed:12531805 ]
  2. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003 Nov 15;9(15):5465-76. [PubMed:14654525 ]
  3. Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94. [PubMed:14753710 ]
  4. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H: Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des. 2004;10(16):1867-83. [PubMed:15180525 ]
  5. Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10. [PubMed:15304385 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in inn...
Gene Name:
CSF1R
Uniprot ID:
P07333
Molecular Weight:
107982.955 Da
References
  1. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. [PubMed:16648572 ]
  2. Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007 May 4;356(2):323-8. Epub 2007 Mar 7. [PubMed:17367763 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, Van Oosterom A, Marynen P, Debiec-Rychter M: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res. 2006 Apr 15;12(8):2622-7. [PubMed:16638875 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
  2. Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29. [PubMed:18971320 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. doi: 10.1158/1078-0432.CCR-09-0048. Epub 2009 Sep 22. [PubMed:19773380 ]
  2. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821 ]
  3. Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29. [PubMed:18971320 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 14:11 / Updated on September 26, 2016 02:12